Connect with us

Economics

Exact Sciences Awards Grants to Federally Qualified Health Centers Focused on Improving Colorectal Cancer Screening of Vulnerable Populations

Exact Sciences Awards Grants to Federally Qualified Health Centers Focused on Improving Colorectal Cancer Screening of Vulnerable Populations
PR Newswire
MADISON, Wis., Sept. 22, 2022

MADISON, Wis., Sept. 22, 2022 /PRNewswire/ — Exact Sciences Cor…

Published

on

Exact Sciences Awards Grants to Federally Qualified Health Centers Focused on Improving Colorectal Cancer Screening of Vulnerable Populations

PR Newswire

MADISON, Wis., Sept. 22, 2022 /PRNewswire/ -- Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, today awarded $525,000 in grants to eight federally qualified health centers focused on improving colorectal cancer screening rates in vulnerable populations.

Colorectal cancer (CRC) is treatable in 90% of cases when detected earlyi, yet approximately 44 million average-risk Americans over age 45 remain unscreened.ii Half of premature colon cancer deaths are due to racial/ethnic, socioeconomic, and geographic inequalities.iii Black Americans are most likely to develop colorectal cancer, and most likely to die from it.iv Hispanic Americans have the second-highest death rate.iv

"Exact Sciences is energized by the call to action within the Biden Administration's Cancer Moonshot plan and recognizes the important role our company can play in defeating cancer," said Dr. Durado Brooks, deputy chief medical officer, Screening at Exact Sciences. "Through our new national FOCUS program, we're committed to expanding equitable access to early detection and reducing barriers to cancer care within our communities."

Exact Sciences' new health equity program, Funding Opportunities for CRC Screening Uptake Strategies (FOCUS), provides grant funding to community organizations focused on addressing these disparities. Awardees will utilize the funds to implement evidence-based and informed intervention strategies proven to increase colorectal cancer screening rates. These include supporting the screening recovery after COVID-19, improving clinic practices to assist patients with the screening process, working with pharmacists to increase access to screening options, and enhancing patient navigation efforts.

Exact Sciences developed Cologuard®, the first and only FDA-approved, non-invasive, multi-target, stool-based DNA screening test. Since making the test available in 2014, more than 9 million people have used Cologuard to screen for colon cancer at home.

Exact Sciences reviewed submissions via its corporate grants process which is fully independent from sales and marketing activities. Funding decisions were solely based on the strength of the application and alignment to the FOCUS Program objectives, without regard to any actual or potential commercial relationship with potential grantees. 

Awardees

Access Community Health Center
Madison, WI
Access Community Health Centers will use funding from the Exact Sciences 2022 FOCUS Program to increase colorectal cancer screening rates for our patients. Access serves a racially and ethnically diverse patient population with high rates of poverty, many of whom experience significant health disparities. This funding will provide culturally appropriate patient education materials; provide staff and provider education on effective screening best practices; outreach to patients who are overdue for colorectal cancer screening; and work with patients to decrease barriers to screening.

AtlantiCare Health Services
Atlantic City, NJ
The funding will increase colorectal cancer screening to support vulnerable populations in Atlantic County. AtlantiCare will work to reducing barriers to follow-up colonoscopy adherence, promote and improve compliance for screening average risk adults, ages 45-75. Additionally, AtlantiCare will focus on building stronger communities through new and maintained collaboration with community stakeholders.

Community HealthCare Network, Inc
New York, NY
Community Healthcare Network (CHN) will implement a comprehensive, integrated colorectal cancer Navigation program with a hyper-focus on the vulnerable and under screened patient populations, especially uninsured patients, ages 45-55. The program will be led by a Cancer Care Manager, whose role it will be to ensure colon cancer screening efficacy at all CHN health centers throughout New York City. By targeting individuals with the lowest screening rates CHN aims to lower the burden of advanced colon cancer within the communities it serves.

Angeles Community Health Center
Los Angeles, CA
As a Federally Qualified Health Center, Angeles consistently screens for colorectal cancer. Using its already-in-place process for screening patients, Angeles will examine and report on colorectal cancer screenings specifically for low-income, Latino patients ages 45-75 of Angeles patient population.

Mariposa Community Health Center
Santa Cruze County, AZ
MCHC is the largest primary care provider in Santa Cruz County, Arizona. As colorectal cancer (CRC) is the second leading cause of cancer-related death in the United States, MCHC aims to decrease death rates due to colon cancer and increase identification of early-stage colon cancer in the county by launching a pharmacist-led screening campaign. The MCHC Clinical Pharmacy Team, in collaboration with MCHC Community Health Workers, has led a successful program to serve its patients with type 2 diabetes mellitus. Because epidemiological data have demonstrated a significant association between the presence of type 2 diabetes mellitus and the development of colorectal cancer, MCHC aims to focus on this population.

Mount Sinai Internal Medicine Associations
New York, NY
The Cologuard stool DNA test is a cost-effective strategy to improve equity in colorectal cancer screening. At a large primary care clinic at The Mount Sinai Hospital serving a vulnerable urban population, orders have significantly increased but completion is limited by suboptimal rates of kit return. Based on our experience with tailored patient navigation, we propose a model in which patients receive tablet-based video instruction at point of order, and a patient navigator will reinforce instructions and overcome patient-specific barriers. We will also engage providers to improve model adherence, order growth, and overall screening.

Mountain Park Health Center
Phoenix, AZ
Mountain Park Health Center will expand its Colorectal Cancer Screening and Referral Program (CCSR). The program will use a full-time cancer screening navigator and various evidence-based interventions to bring about system change and sustainability for years to come. Expected outcomes include increasing the percentage of adults who had appropriate colorectal cancer screening rates to 50% or more; and improving the number of timely referrals for follow-up care for patients with abnormal test results.

San Joaquin Health Center
Stockton, CA
San Joaquin Health Centers, a FQHC Look-Alike serving California's San Joaquin County serves approximately 30,000 unique patients annually with over 9,000 of its patients aged 45-79. The percentage of patients ages 50 through 75 years of age who had appropriate screening for CRC at San Joaquin Health dropped from 2019 to 2021. To address this, San Joaquin Health will enact multicomponent interventions focused on increasing community/patient demand for colorectal cancer screening, improving community/patient access to CRC screening, and increasing provider delivery of screening. Through these sustainable interventions San Joaquin Health will promote and improve compliance for CRC screening of average risk patients.

About Exact Sciences Corp.

A leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter solutions providing the clarity to take life-changing action, earlier. Building on the success of Cologuard® and Oncotype® tests, Exact Sciences is investing in its product pipeline to support patients before and throughout their cancer diagnosis and treatment. Exact Sciences unites visionary collaborators to help advance the fight against cancer. For more information, please visit the company's website at www.exactsciences.com, follow Exact Sciences on Twitter @ExactSciences, or find Exact Sciences on Facebook and LinkedIn.

About Cologuard

The Cologuard test was approved by the FDA in August 2014, and results from Exact Sciences' prospective 90-site, point-in-time, 10,000-patient pivotal trial were published in the New England Journal of Medicine in March 2014. The Cologuard test is included in the American Cancer Society's (2018) colorectal cancer screening guidelines and the recommendations of the U.S. Preventive Services Task Force (2021) and National Comprehensive Cancer Network (2016). The Cologuard test is indicated to screen adults 45 years of age and older who are at average risk for colorectal cancer by detecting certain DNA markers and blood in the stool. Do not use the Cologuard test if you have had precancer, have inflammatory bowel disease and certain hereditary syndromes, or have a personal or family history of colorectal cancer. The Cologuard test is not a replacement for colonoscopy in high risk patients. The Cologuard test performance in adults ages 45-49 is estimated based on a large clinical study of patients 50 and older. The Cologuard test performance in repeat testing has not been evaluated.

The Cologuard test result should be interpreted with caution. A positive test result does not confirm the presence of cancer. Patients with a positive test result should be referred for diagnostic colonoscopy. A negative test result does not confirm the absence of cancer. Patients with a negative test result should discuss with their doctor when they need to be tested again. Medicare and most major insurers cover the Cologuard test. For more information about the Cologuard test, visit cologuard.com. Rx only. Medicare and most major insurers cover Cologuard. For more information about Cologuard, visit www.cologuard.com.

Forward-Looking Statements
This news release contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs, or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially from those anticipated. You should not place undue reliance on forward-looking statements. Risks and uncertainties that may affect our forward-looking statements are described in the Risk Factors sections of our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

i American Cancer Society. Colorectal Cancer Facts & Figures 2020-2022. Atlanta, GA: American Cancer Society; 2020.

ii Piscitello A, Edwards DK. Estimating the screening-eligible population size, aged 45 to 74, at average risk to develop colorectal cancer in the United States. Cancer Prev Res.2020;13(5):443-448. *Estimate based on the US population aged 45-74 as of 2018, adjusted for the reported rates of high-risk conditions and prior screening history for CRC.

i[i][i] Jemal A, Siegel RL, Ma J, et al. Inequalities in premature death from colorectal cancer by state. J Clin Oncol. 2015;33(8):829-835. doi:10.1200/JCO.2014.58.7519.

iv Annual Report to the Nation on the Status of Cancer, Part I: National Cancer Statistics. Henley; 2021.

Investor Contact:
Megan Jones
Exact Sciences Corp.
meganjones@exactsciences.com
608-535-8815

Media Contact:
Stephanie Miller
Exact Sciences Corp.
stmiller@exactsciences.com
920-470-4618

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/exact-sciences-awards-grants-to-federally-qualified-health-centers-focused-on-improving-colorectal-cancer-screening-of-vulnerable-populations-301630886.html

SOURCE EXACT SCIENCES CORP

Read More

Continue Reading

Economics

Cities With Good Neighbors Have Lower-Than-Average Home Values

New York’s Rochester was identified took the top spot as the most neighborly city in the country.

Published

on

New York's Rochester was identified took the top spot as the most neighborly city in the country.

Many want the kind of neighbor who will stop by with fresh-baked cookies, offer gardening tips and take out the mail while they're away — a thing that, if you live in an urban mecca like New York, is just as likely as finding a spacious apartment that's available and within budget.

In honor of National Neighbor Day on Sept. 28, self-storage company Neighbor.com identified Rochester in the Finger Lakes region of New York state as the most neighborly city in the country.

The study analyzed both big and small cities through factors such as resident happiness levels and number of people volunteering their time to the community.

"It's not a surprise that Rochester is the most neighborly city this year, it's made this list each year," Joseph Woodbury, CEO and co-founder of Neighbor.com, said of the findings. "Oftentimes, we connect hospitality with small cities, but you’ll find that people in large cities are just as likely to go out of their way to help one another."

Correlation Between Neighborliness and Home Values

While Federal Reserve economic data pegs the median price of homes sold in 2022 at $428,000, the median list price identified by Realtor.com for Rochester is $150,000. 

Madison, Wis., and Provo, Utah followed Rochester as the most "neighborly" cities in the U.S. and have respective median list prices of $360,000 and $495,000.

Along with Provo, California's Oxnard breaks the list's mold with its high real estate prices — amid proximity to the beach (the city is about 60 miles from Los Angeles) and quaint Victoria architecture, the city has a median list price of $794,500.

Getty Images

Other cities on the list generally fall below the national average for a standard single-family home. Grand Rapids in Michigan has a median list price of $307,500 while that number is only $175,000 in Milwaukee, Wis.

Harrisburg, Pa., and Des Moines, Iowa are two other neighborly cities with respective list prices of $215,000 and $227,500. 

Good neighbors have long been a hallmark of smaller cities with a quieter way of life — metropolises like New York and Los Angeles have very high property values, they are not exactly known for being "friendly" or "welcoming."

With a median list price of $495,000, North Carolina's Raleigh is the largest city to make the list.

Those who think New Yorkers are unfriendly need only to look outside the five boroughs — with a median list price of $334,000, Poughkeepsie also made the list for its neighborliness.

Search For the Next Big Real Estate City

As sleepy towns that paint a TV image of "neighborliness" tend to have lower demand, they may not offer the kind of real estate growth potential that many investors are specifically looking for. 

But exceptions do exist — many small cities are currently in the midst of a real estate boon and, subsequently, an explosion in real estate values.

Action Alerts Plus

The Best Ideas For You To Build Wealth

A members-only investing club that helps you grow your portfolio with real-time trade alerts, analysis of major market events, and key opportunities.

  • Real-Time Trade Alerts
  • 24/7 Access To The Portfolio
  • Portfolio Price Targets

According to the study's authors, many homebuyers looking to move have specifically started looking for "friendlier" cities after the pandemic and are driving up demand for formerly quiet places.

Realtor.com identified Utah's Salt Lake City, Idaho's Boise and Washington state's Spokane as 2022's fastest-growing real estate markets.

"Being neighborly goes beyond a friendly wave while driving down the street or offering to water plants while on vacation," Woodbury said. "To be neighborly is opening yourself up to building relationships and ultimately a community that is rooted in compassion, trust, and care."

Read More

Continue Reading

Economics

Here’s Why Your Boss May Reject Your Business Travel Request

People are taking vacations again, but a once dominant travel sector is struggling to recover.

Published

on

People are taking vacations again, but a once dominant travel sector is struggling to recover.

Now that vaccines are readily available and President Joe Biden has declared that the pandemic is officially over, people are flying again. But they’re really not happy about it.

The research firm J.D. Power found that last year, when the airline industry first started to cautiously rebound, consumer satisfaction with airports reached an all-time high. But this was very likely both because of a relatively smaller sample size and that so many people were happy to fly again that they were willing to overlook a lot of what has become headache-inducing about modern airfare travel.

J.D. Power  (JD) - Get JD.com Inc. Report has found that this year, global passenger levels are nearly back up to 91% of pre-pandemic levels. 

Customer satisfaction has dropped sharply, 25 points on a 1,000-point scale, to 777, as more people have returned to airports, for reasons ranging from an increase in flight cancellations and delays to inflation-driven increases in the cost of airport food.

But while airlines are aware that customers aren’t happy, and that the Biden Administration might try to right the ship with proposals that airlines likely won’t care for, at least people are flying again.

But an additional survey by J.D. Power has revealed that while people are flying again, traveling for business (be it for in-person meetings or industry conferences), has been lagging behind and recovering at nearly the rate of traveling for pleasure. 

Is Traveling for Business on the Way Out?

J.D. Power’s research has found that many travelers doubt that travel levels will increase dramatically from where they are now, and that “a strong majority of executives believe their companies will spend less in the next six months compared to the same period in 2019, for instance, due to things like fewer trips overall or fewer employees sent when there is a trip scheduled,” according to their data.

Overall, business travel has returned to “about 81% of 2019 levels,” notes Managing Director Michael Taylor. “83% was our prediction for this quarter, we’ll see how well we did in a few weeks and add a predication for Q4.”

J.D. Power

Fears of recession and the rising costs of air tickets from inflation play a factor in the decline of business travel. But overall, the main reason is that many of us have gotten so used to working at home that two-thirds of employees would rather find a new job than go back to the pre-pandemic status quo. If employees feel they can get work done from home and don’t feel like braving traffic to return to the office, why would they feel they need to get on a plane?

So have services like Zoom (ZM) - Get Zoom Video Communications Inc. Report and Slack made the business trip redundant? Taylor has his doubts.

“But will people be meeting exclusively in the 'Metaverse' rather than in person? I do not think that will happen,” he says. “There is too much information to be gathered in face-to-face meetings, spoken and unspoken, to be replaced completely by virtual ‘reality.’”

Getty Images

So is This It for Business Travel?

Back in the heady pre-pandemic days three years ago, airlines could rely on the extra income from people whose jobs entailed a great deal of travel, and who had come to the realization that if they were going to spend a chunk of their lives on the road, they could splurge to make it a more comfortable experience. 

But if airlines want this sector to return, Taylor thinks it’s their duty to make it a more appealing option, because frequent delays and other headaches are enough to make anyone stick to Zoom.

Action Alerts Plus

The Best Ideas For You To Build Wealth

A members-only investing club that helps you grow your portfolio with real-time trade alerts, analysis of major market events, and key opportunities.

  • Real-Time Trade Alerts
  • 24/7 Access To The Portfolio
  • Portfolio Price Targets

Airlines, Taylor says, must “create more of a “living room” experience for travelers, one that “makes travelers feel valued as patrons of the airlines, and makes people feel like individuals rather than cattle.”

Because while it’s hard to argue with the convenience, Taylor insists there is still something to be said for the occasional in-person meeting. 

“Millenia of evolution in mankind has created an awareness that can’t be described with words on a page or pixels on a screen,” he says. “People will still find advantages in meeting in-person rather than online.”

Read More

Continue Reading

Economics

BOEHRINGER INGELHEIM DONATES NEARLY 100,000 PET VACCINE DOSES TO HELP ELIMINATE RABIES AROUND THE WORLD WITH RELAUNCH OF SHOTS FOR GOOD(SM) INITIATIVE

BOEHRINGER INGELHEIM DONATES NEARLY 100,000 PET VACCINE DOSES TO HELP ELIMINATE RABIES AROUND THE WORLD WITH RELAUNCH OF SHOTS FOR GOOD(SM) INITIATIVE
PR Newswire
DULUTH, Ga., Sept. 28, 2022

In recognition of World Rabies Day on September 28, the d…

Published

on

BOEHRINGER INGELHEIM DONATES NEARLY 100,000 PET VACCINE DOSES TO HELP ELIMINATE RABIES AROUND THE WORLD WITH RELAUNCH OF SHOTS FOR GOOD(SM) INITIATIVE

PR Newswire

In recognition of World Rabies Day on September 28, the donation is for use on tribal lands and underserved communities in collaboration with Greater Good Charities

DULUTH, Ga., Sept. 28, 2022 /PRNewswire/ -- Boehringer Ingelheim, a global leader in veterinary rabies vaccines, has expanded its commitment to help prevent rabies in dogs by donating nearly 100,000 doses of rabies vaccine. The donation is part of the relaunched SHOTS FOR GOOD℠ program and will be used on tribal lands and in underserved communities across the United States.

Rabies is a zoonotic, viral disease, which can be transmitted through wild animals and pets. Once clinical symptoms appear, rabies is virtually 100% fatali. Even though it is vaccine-preventable, around 59,000 people still die from rabies every year globallyii. Rabies is present on all continents, except Antarctica, with over 95% of human deaths occurring in the Asia and Africa regionsiii. It can pose a significant risk anywhere if dogs are not vaccinated. Dogs are the main source of human rabies deaths, contributing up to 99% of all rabies transmissions to humansiv.

"Boehringer Ingelheim fervently believes no animal should suffer from a preventable disease," said Dr. Julie Ryan-Johnson, head veterinarian for shelters at Boehringer Ingelheim and board vice chair for Greater Good Charities. "Together with Greater Good Charities we can fight the presence of rabies on tribal lands and in underserved communities to keep pets healthier and happier for longer."

Boehringer Ingelheim Animal Health established the SHOTS FOR GOOD initiative in 2019 in Puerto Rico and underserved communities in California, Nevada, Oklahoma, Texas, North Carolina, Louisiana, Mississippi, and Florida. However, in 2020, the initiative was suspended due to global pandemic restrictions.

Since relaunching the program earlier this year, and in collaboration with the global nonprofit, Greater Good Charities, the program has enabled vaccination clinics throughout tribal lands in Alaska, Arizona, Colorado, Montana, and Utah. Additional vaccines have been utilized in Hawaii as part of Greater Good Charities' Good Fix program which offers high-quality, high-volume spay/neuter to help control pet overpopulation in underserved communities.

"In observance of World Rabies Day, we recognize the positive impact of vaccination events to raise awareness about rabies and how to prevent this deadly disease," said Denise Bash, vice president at Greater Good Charities. "The generous vaccine donations from Boehringer Ingelheim Animal Health and the Shots for Good initiative helps to protect pets while making this important effort possible."

About World Rabies Day

World Rabies Day, held every year on September 28, is observed by the United Nations as an International Day. Coordinated by the Global Alliance for Rabies Control, it is a day to raise awareness about rabies and how to prevent this deadly disease. Hundreds of events are held by organizations and individuals around the world in recognition of this day.

About Boehringer Ingelheim

Boehringer Ingelheim Animal Health is working on first-in-class innovation for the prediction, prevention, and treatment of diseases in animals. For veterinarians, pet owners, farmers, and governments in more than 150 countries, we offer a large and innovative portfolio of products and services to improve the health and well-being of companion animals and livestock. As a global leader in the animal health industry and as part of family-owned Boehringer Ingelheim, we take a long-term perspective. The lives of animals and humans are interconnected in deep and complex ways. We know that when animals are healthy, humans are healthier too. By using the synergies between our Animal Health and Human Pharma businesses and by delivering value through innovation, we enhance the health and well-being of both.

Learn more about Boehringer Ingelheim Animal Health USA Inc. at bi-animalhealth.com  

About Greater Good Charities

Greater Good Charities is a 501(c)(3) global nonprofit organization that works to help people, pets, and the planet by mobilizing in response to need and amplifying the good. Greater Good Charities, with a 100/100 rating on Charity Navigator, has provided more than $475 million in impact, including cash grants, in-kind supplies, and programmatic support, to charitable partners in 121 countries since 2007. To learn more about how Greater Good Charities amplifies the good across the globe, please visit greatergood.org.

Media Contact:
Chrissy Jones
Boehringer Ingelheim Animal Health
U.S. Communications
(516) 527-5456
christine.jones@boehringer-ingelheim.com 

REFERENCES

i World Health Organization: Rabies (who.int) (downloaded: April 1, 2022)
ii World Health Organization: Oral rabies vaccine: a new strategy in the fight against rabies deaths (who.int) (downloaded: April 1, 2022)
iii World Health Organization: Rabies (who.int) (downloaded: April 1, 2022)
iv World Health Organization: Rabies (who.int) (downloaded: April 1, 2022)

View original content to download multimedia:https://www.prnewswire.com/news-releases/boehringer-ingelheim-donates-nearly-100-000-pet-vaccine-doses-to-help-eliminate-rabies-around-the-world-with-relaunch-of-shots-for-goodsm-initiative-301636061.html

SOURCE Boehringer Ingelheim

Read More

Continue Reading

Trending